|
2016年5月23日，美國臨床腫瘤學會（ASCO）官方期刊《臨床腫瘤學雜志》（JCO）在線發(fā)表美國（加利福尼亞大學、美國臨床腫瘤學會、弗吉尼亞癌癥研究所、哥倫布腫瘤與血液學會、密歇根大學、明尼蘇達州伊代納患者代表、紐約紀念斯隆·凱特林癌癥中心、威爾·康奈爾醫(yī)學院、薩塞克斯大學、梅奧醫(yī)院、邁阿密大學、華盛頓大學、北卡羅來納大學、哈佛醫(yī)學院達納法伯癌癥中心）和英國（倫敦皇家馬斯登醫(yī)院）起草的《激素受體陽性轉(zhuǎn)移性乳腺癌內(nèi)分泌療法：ASCO指南》，包括正文37頁、數(shù)據(jù)10頁、方法13頁、幻燈PPT版和PDF版各20頁、推薦意見匯總表5頁、流程圖2頁，點擊左下角“閱讀全文”可免費下載↙ 這是JCO發(fā)表的首部轉(zhuǎn)移性乳腺癌內(nèi)分泌療法ASCO指南，此前發(fā)表的均為早期乳腺癌術后輔助內(nèi)分泌療法ASCO指南：
由于該指南涉及許多中國尚未上市或批準的新藥物或新療法，故僅供乳腺癌專業(yè)人士、乳腺癌專業(yè)英語愛好者參考，非專業(yè)人士、非英語愛好者請直接參考中國指南，謝謝！ J Clin Oncol. 2016 May 23. [Epub ahead of print] Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Klein Connolly, Maura N. Dickler, Lesley Fallowfield, Barbara Fowble, James N. Ingle, Mohammad Jahanzeb, Stephen R.D. Johnston, Larissa A. Korde, James L. Khatcheressian, Rita S. Mehta, Hyman B. Muss, Harold J. Burstein. University of California San Francisco Comprehensive Cancer Center; University of California San Francisco, San Francisco; University of California Irvine, Orange, CA; American Society of Clinical Oncology, Alexandria; Virginia Cancer Institute, Richmond, VA; Columbus Oncology and Hematology Associates, Columbus, OH; University of Michigan School of Nursing, Ann Arbor, MI; Patient Representative, Edina, MN; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Royal Marsden Hospital, London, United Kingdom; Mayo Clinic, Rochester, MN; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; University of Washington, Seattle, WA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Dana-Farber Cancer Center, Boston, MA. PURPOSE: To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. RECOMMENDATIONS: Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates. DOI: 10.1200/JCO.2016.67.1487
|
|
|
